%0 Journal Article
%A Schober, T.
%T Composites of ceramic high-temperature proton conductors with inorganic compounds
%J Electrochemical and solid-state letters
%V 8
%@ 1099-0062
%C Pennington, NJ
%I Soc.
%M PreJuSER-45393
%P A199 - A200
%D 2005
%Z Record converted from VDB: 12.11.2012
%X This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
%K J (WoSType)
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:000228326500006
%R 10.1149/1.1865592
%U https://juser.fz-juelich.de/record/45393